Omeros Corporation
OMERNext catalyst
OMS906 study drug
Paroxysmal Nocturnal Hemoglobinuria
Get an email about OMER's next catalysts
Track Omeros (OMER) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 0 past
OMER Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.05 | FQ end Sep/2026 | Call: tbd
OMS906 study drug Phase 2 Est. Readout
Primary completion for OMS906 study drug trial (NCT06298955) in Paroxysmal Nocturnal Hemoglobinuria
SourceMarket Overview
Stock performance and key metrics
Phenylephrine HCl
Unilateral Cataract Extraction
OMS103HP-S
Meniscal Tear
OMS302
Intraocular Lens Replacement
OMS103HP
Anterior Cruciate Ligament Reconstruction
OMS302-PE
Cataract Extraction
OMS906
Paroxysmal Nocturnal Hemoglobinuria
OMS302 Solution
Cataract
narsoplimab
Thrombotic Microangiopathies
OMS643762
Schizophrenia
pioglitazone
Opioid Abuse
OMS302 Anti-inflammatory Solution
Cataract
OMS302 Mydriatic Solution
Cataract
OMS201
Urinary Calculi
OMS721
Thrombotic Microangiopathies
OMS906 study drug
Paroxysmal Nocturnal Hemoglobinuria
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Phenylephrine HCl | Phase 3 | Unilateral Cataract Extraction | - | - |
OMS103HP-S | Phase 3 | Meniscal Tear | - | - |
OMS302 | Phase 3 | Intraocular Lens Replacement | - | - |
OMS103HP | Phase 3 | Anterior Cruciate Ligament Reconstruction | - | - |
OMS302-PE | Phase 2 | Cataract Extraction | - | - |
OMS906 | Phase 2 | Paroxysmal Nocturnal Hemoglobinuria | - | - |
OMS302 Solution | Phase 2 | Cataract | - | - |
narsoplimab | Phase 2 | Thrombotic Microangiopathies | - | - |
OMS643762 | Phase 2 | Schizophrenia | - | - |
pioglitazone | Phase 2 | Opioid Abuse | - | - |
OMS302 Anti-inflammatory Solution | Phase 2 | Cataract | - | - |
OMS302 Mydriatic Solution | Phase 2 | Cataract | - | - |
OMS201 | Phase 2 | Urinary Calculi | - | - |
OMS721 | Phase 2 | Thrombotic Microangiopathies | - | - |
OMS906 study drug | Phase 2 | Paroxysmal Nocturnal Hemoglobinuria | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Omeros Corporation's drug pipeline?→
CatalystAlert tracks 15 drug candidates in Omeros Corporation's (OMER) pipeline across Phase 3, Phase 2. Its lead program is OMS103HP (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Omeros Corporation's next FDA catalyst?→
Omeros Corporation's (OMER) next tracked catalyst is a Phase 2 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track OMER biotech catalysts?→
Add OMER to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Omeros Corporation's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.